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Abstract  
 
Background: The present paper provides an updated review of both the large 
number of new/novel/emerging psychoactive substances (NPS) and their 
associated psychopathological consequences. Focus was here given on 
identification of those NPS being commented in specialised online sources and 
the related short-/long-term psychopathological and medical ill-health effects.  
Methods: NPS have been identified through an innovative crawling/navigating 
software, called the ‘NPS.Finder®’, created in order to facilitate the process of 
early recognition of NPS online. A range of information regarding NPS, 
including chemical and street names; chemical formula; three-dimensional 
image; and anecdotally reported clinical/psychoactive effects, were here made 
available. 
Results: Using the ‘NPS.Finder®’ approach, a few thousands NPS were here 
preliminarily identified, a number which is about 4-fold higher than those 
figures suggested by European and international drug agencies. NPS most 
commonly associated with the onset of psychopathological consequences 
included here synthetic cannabinoids/cannabimimetics; new synthetic opioids; 
ketamine-like dissociatives; novel stimulants; novel psychedelics; and several 
prescription and over-the-counter medicines.  
Conclusions: The ever-increasing changes in terms of recreational 
psychotropics’ availability represents a relatively new challenge for psychiatry, 
as the pharmacodynamics and pharmacokinetics of many NPS have not been 
thoroughly understood. Health/mental health professionals should be informed 
about the range of NPS; their intake modalities; their psychoactive sought-
after effects; the idiosyncratic psychotropics’ combinations; and finally their 
medical and psychopathological risks.  
 
 
Key words: new psychoactive substances; NPS; psychedelics; drug-induced 
psychosis; prescribing drug misuse; drug misuse. 
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Introduction  
 
Several definitions of the term novel/new psychoactive substances (NPS) are in 
use, with the term ‘new’ not necessarily referring to new inventions but to 
substances that have recently been made available ([UNODC], 2013). Hence, 
‘new’ can include a failed pharmaceutical or an old patent which has been 
‘rediscovered’ and marketed for its potential use as a ‘recreational’ substance. 
Conversely, the term ‘novel’ can also express something newly created, or a 
compound that has come back into fashion after a period of absence from the 
recreational drug scene, or indeed a known NPS molecule being used in an 
innovative or unusual way, hence presenting with a ‘novelty’ appeal (Corkery 
et al., 2018a). Another distinction being made is between NPS and Emerging 
Psychoactive Substances (EPS), where the latter term captures all NPS as well 
as drugs that may not be newly invented, but have recently experienced a 
resurgence of, or increase in, use (Sutherland and Barratt, 2016). 
 
Number and types of NPS in both real and online scenarios  
Between 2009 and 2017, a total of 803 NPS were reported by 111 
countries/territories (UNODC, 2018). In the EU, by the end of 2017 the 
number of NPS was over 670, of which 632 were notified after 2004 
([EMCDDA], 2018a); most molecules were synthetic cannabinoids, synthetic 
cathinones, phenethylamine derivatives; and synthetic opioids.  
Both the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) 
and the United Nations Office on Drugs and Crime (UNODC), however, include 
an index NPS in their database only when the NPS is seized, chemically 
analysed and notified to them. However, one could argue that the NPS 
scenario is much larger than that formally identified by international agencies. 
Hence, an approach aiming at describing what is being discussed online by the 
web-based NPS enthusiasts ‘e-psychonauts’ (Orsolini et al., 2015) has been 
considered as potentially useful to identify in advance the NPS availability, 
market and diffusion. In fact, the online NPS scenario, with its related 
concerns, typically predicts the real life NPS scenario (Corazza et al., 2013). 
Consistent with this, a risk of violent behaviour associated with NPS intake has 
been identified in patients presenting to London (UK) acute mental health 
services (Shafi et al., 2017). Furthermore, both the psychopathological and 
aggression issues associated with the Ibiza clubbing scenario drug intake 
(Martinotti et al., 2017) had been somehow predicted by previous studies 
(Schifano et al, 2015; Schifano et al, 2016) based on the observation of the 
evolving ‘e-psychonauts’ scenario.   
 
Aims 
In this study, we aimed at: (a) identifying and describing the large number of 
NPS available as identified from a range of psychonauts’, NPS-related, online 
sources; and (b) describing the short-/long-term clinical effects of the NPS 
most commonly associated with the onset of those psychopathological 
consequences which are of interest for mental health professionals. These NPS 
include: synthetic cannabinoids/cannabimimetics; new synthetic opioids; 
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ketamine-like dissociatives; novel stimulants and novel psychedelics; 
prescription; and over-the-counter (OTC) medicines (Schifano et al., 2015).  
 
Methods 
To facilitate the process of early recognition of the increasing dissemination of 
new substances online and the variability of information sources, a 
crawling/navigating software (i.e. the ‘NPS.Finder®’) was designed to 
automatically scan the open/surface web for new/novel/emerging NPS. This 
was meant to map on a 24/7 basis the large variety of psychoactive molecules 
mentioned/discussed within a range of major and representative online 
psychonaut web sites/fora (the full list of these sites is available upon 
request). The NPS.Finder® was designed to extract a range of information 
regarding NPS, including: chemical and street names; chemical formula; three-
dimensional image; and anecdotally reported clinical/psychoactive effects. 
Resulting data were checked against the EMCDDA and UNODC NPS databases. 
The collection of further information was completed by consulting a range of 
open libraries and chemistry databases referring to the index item, if existing. 
These data were then automatically stored in an online, restricted 
access/password-controlled database located within firewall protected, highly 
secure, and consistently performing servers. After completion of proper piloting 
searches, a range of specific web scraper/crawler activities, to extract all 
accessible posts/entries from November 26th, 2017 and up to end of May 2019, 
were carried out. When any new item was detected during the automated web 
scan, the system sent an e-mail notification/alert to the core researchers’ 
mailing list. Eventually, these data were screened for relevance and to exclude 
possible duplications. Finally, using chemical structure identification and 
published related data, researchers assigned each molecule to its NPS drug 
class (Schifano et al., 2015). Although the language most typically used by 
psychonauts was English, further languages here analyzed by NPS.Finder® 
included: Dutch, French, Turkish, Swedish, Spanish, German, Russian, and 
Italian. 
To describe the medical and psychopathological issues most typically 
associated with the range of NPS intake, the Medline/PubMed database(s), 
were searched for papers using the terms ‘new psychoactive substances’, 
‘novel psychoactive substances’, ‘designer drugs’, and ‘emerging drugs of 
abuse’. A similar search was carried out for the main groups of pre-selected 
NPS molecules and related medical and psychopathological consequences.  
 
Results 
Preliminary data from the NPS.Finder® web crawling activities 
After about 18 months of operation, the number of substances identified by the 
web crawler activities was 5922. By the time of writing, some 4,204 unique 
NPS molecules were included in the database and 1718/5922 (29.01%) 
remaining molecules resulted to be false positives/duplicates. Most popular 
NPS mentioned in the psychonauts’ fora included: psychedelic 
phenethylamines (1262; 30%); synthetic cannabimimetics (1248; 29.7%); 
synthetic opioids (460; 10.9%); GABA-A/GABA-B receptor agonists (172; 
4.1%); synthetic cathinones (171; 4.1%); prescribed/OTC medicinal 
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compounds (157; 3.7%); novel stimulants (82; 1.9%); novel psychedelics 
(38; 0.9%); and PCP/ketamine-like compounds (36; 0.8%).  
 
Synthetic cannabinoids/cannabimimetics (SC) 
Whilst low-dosage levels of synthetic cannabinoids (SC) produce similar 
psychoactive effects to cannabis/THC, with higher dosages auditory/visual 
hallucinations, anxiety, and intense feelings of paranoia often occur 
(Bonaccorso et al., 2018; Wessinger et al., 2015; Winstock and Barratt, 
2013a). Other psychiatric and neurological effects include: behavioural 
dyscontrol and agitation (Brakoulias, 2012); mood swings (Celofiga et al., 
2014); suicidal ideation, suicide attempts (Glue et al., 2013); panic attacks; 
thought disorganisation; and agitated/excited delirium (Schifano et al., 2017). 
A florid/acute/transient psychosis; relapse/worsening of a pre-existing 
psychosis and bipolar disorder (Oluwabusi et al., 2012; Ustundag et al., 2015); 
and the persistent psychotic disorder ‘spiceophrenia’ (Papanti et al., 2013; 
Schifano et al., 2016) have all been described. With synthetic cannabinoids, 
similar to what being described for a range of remaining NPS (Schifano et al, 
2015), the total or partial recurrence of perceptual disturbances that appeared 
during previous hallucinogenic intoxications, typically known as Hallucinogen-
Persisting Perception Disorder (HPPD), may occur (Martinotti et al., 2018). 
The intoxication/acute toxic effects of SCs appear to be more akin to those 
experienced with sympathomimetic/stimulant drug use (Naviglio et al., 2015; 
Wood and Dargan, 2012). Typical medical untoward effects include: 
vomiting/nausea; hypertension and tachycardia; tachypnoea/dyspnoea; 
hyperglycaemia; mydriasis (Hermanns-Clausen et al., 2013; Schifano et al., 
2015; Winstock and Barratt, 2013b); nystagmus; seizures (Hopkins and 
Gilchrist, 2013); encephalopathy (Louh and Freeman, 2014); coma; and stroke 
(Freeman et al., 2013; Mir et al., 2011; Rose et al., 2015). Ultimately, deaths 
have been associated with the use of synthetic cannabinoids, either on their 
own or in combination (Angerer et al., 2017; Corkery et al., 2014; Maeda et 
al., 2018; Olsen, 2018; Paul et al., 2018; Tait et al., 2015; Trecki et al., 
2015). These may result from direct lethality of the molecule; behavioural 
dyscontrol; or suicide (Lászik et al., 2015; Patton et al., 2013; Rosenbaum et 
al., 2012; Shanks et al., 2012).  
Finally, SC long-term use can give rise to dependence/tolerance phenomena 
(Gunderson et al., 2012; Spaderna et al., 2013); a withdrawal syndrome, 
characterized by: profuse sweating, tachycardia, tremor, diarrhoea, headache, 
drug craving, feelings of emptiness/depression, anxiety, irritability, mood 
swings, and insomnia/nightmares has been described (Macfarlane and Christie, 
2015). 
 
New Synthetic Opioids (NSOs) 
New synthetic opioids (NSOs) emerged in recent years as part of the alarming 
worldwide opioid crisis (Armenian et al., 2018; [CDC], 2016; [CDC], 2018; 
Drummer, 2018; [EMCDDA], 2017; Graddy et al., 2018; Lucyk and Nelson, 
2017; Prekupec et al., 2017; Suzuki and El-Haddad, 2017; Van Amsterdam 
and van den Brink, 2015). NSOs are a large group of narcotic analgesic drugs 
having structural similarities, but much greater potency of action and receptor 
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affinity, with respect to morphine (Marchei et al., 2018; Solimini et al., 2018; 
Tracy et al., 2017). This group includes compounds which were originally 
synthesized by pharmaceutical companies but never commercialised and then 
diverted into the illegal market, e.g. benzamide (U-47700, U-49900, AH-
7921); acetamide (U-50488, U-51754); piperazine derivatives (MT-45) 
(Zawilska, 2017); and several illicitly manufactured fentanyl analogues, e.g. 
acetylfentanyl; carfentanyl; furanylfentanyl; 3-methylfentanyl; sufentanyl; etc. 
(Armenian et al., 2018; Marchei et al., 2018; Suzuki and El-Haddad, 2017). 
These molecules may be used alone; as adulterants in heroin; or as 
constituents of other illicit products or counterfeit medications (Abdulrahim and 
Bowden-Jones, 2018; Prekupec et al., 2017).  
NSOs’ toxicity includes drowsiness, sedation, disorientation, slurred speech, 
confusion, dizziness, nausea, miosis, slowed breathing and respiratory 
depression to coma (Suzuki and El-Haddad, 2017). Conversely, NSOs’ 
psychotropic effects include: sedation; euphoria; feeling of relaxation; mood 
lift, dysphoric and dissociating effects (Solimini et al., 2018) (Table 1).  
Due to their high potency, their continued use (or abuse) may induce 
tolerance, with the risk of overdose and death being elevated. Physical 
dependence and addiction may rapidly rise, and withdrawal symptoms occur if 
their use is rapidly reduced or suddenly stopped. These include symptoms 
similar to the traditional opioid withdrawal, such as restlessness, agitation, 
muscle and bone pain, insomnia, diarrhoea, vomiting, and cold flashes with 
goose bumps (Suzuki and El-Haddad, 2017; Zawilska, 2017).  
Other compounds classified among NSOs are desomorphine (‘krokodil’), 
mitragynine and 7-hydroxymitragynine (alkaloids found in “kratom”/Mitragyna 
speciosa; Liu et al., 2018; Corkery et al, in press), and salvinorin A, with its 
analogue herkinorin, which are the main Salvia divinorum components. 
Salvinorin A psychoactive effects include perceptual disturbances, psychosis, 
irritability, and anxiety (Ventura et al., 2018) (Table 1). 
 
Ketamine-like dissociatives 
Ketamine and phencyclidine (PCP) were both originally developed as general 
anaesthetics for veterinary and human use, but soon became street drugs. 
Despite the strong dissociative effects on post-operative patients, ketamine is 
used as anaesthetic mostly in veterinary practice, but also in emergency 
medicine (Baumeister et al., 2015). Ketamine (‘special K’) can be injected, 
snorted, smoked, or administered rectally, at a dosage range of 25-300 mg, 
inducing feelings of relaxation, dissociation, depersonalization, and psychotic 
experiences, with hallucinations lasting even longer than the anaesthetic 
effects. 
Ketamine intoxication may include cardiovascular and respiratory symptoms 
and, due to its anaesthetic and dissociative effects, related risks may include 
trauma, drowning, death from hypothermia and traffic accidents (Schifano et 
al., 2015) (Table 1). The ‘K-hole’, which may result after the ingestion of large 
dosages of ketamine, is a typical out-of-body/near-death experience, with the 
user becoming trapped in a state of detachment from his/her physical 
presence. Residual symptoms, such as flashbacks and perceptual distortions, 
may follow.  
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Long‐term ketamine use may present with both urological (‘K-bladder’) and 
intestinal (‘K-cramps’) symptoms (Schifano et al., 2015). Compared with 
ketamine, PCP (‘angel dust’) appears to determine much wider and unstable 
range of symptoms, with cerebrovascular accidents and cardiac arrest 
occurring (Baumeister et al., 2015). Chronic use of PCP may impair memory 
and thinking, and determine mood shifts, anxiety and suicidal thoughts ([DEA], 
2013) (Table 1).  
Further related dissociatives recently entered the market (Wallach et al., 
2016), including: 4-MeO-PCP (Morris and Wallach, 2014); the 1,2-
diarylethylamines (e.g. diphenidine, ephenidine, methoxydiphenidine and 
various analogues such as fluorolintane and N-ethyl-lanicemine); and the β-
keto-arylcyclohexylamines (e.g. methoxetamine, deschloroketamine, and 2-
fluoro-2-deschloroketamine) molecules (Wallach and Brandt, 2018). They 
primarily act as uncompetitive antagonists at glutamatergic NMDA receptors, 
but may also bind at opioid and monoaminergic receptors (Schifano et al., 
2015). Their effects are diverse and dose-dependent, generally inducing a 
mind-altering state, with sensory hallucinations, tactile distortions, euphoria, 
derealization and depersonalization (Tracy et al., 2017; Wallach et al., 2016) 
(Table 1).  
 
Novel stimulants and novel psychedelics, including psychedelic 
phenethylamines 
Novel stimulant and novel psychedelic compounds include phenethylamines, 
cathinones, piperazines, tryptamines, pipradrols/piperidines, aminoindanes, 
benzofurans, and amphetamines; all of these present with varying levels of 
stimulant, entactogenic, and hallucinogenic effects. They exert an inhibitory 
action on the monoamine reuptake, increasing the quantity of 
noradrenaline/NA, dopamine/DA and serotonin/5-HT in the synaptic cleft 
(Miliano et al., 2016). Consistent with their pharmacological profile, those 
molecules that present with high serotonin:dopamine ratios may be considered 
analogous to entactogenic substances, such as MDMA. Conversely, high 
dopamine:serotonin ratios might predict a strong stimulant experience. 
Furthermore, high or low affinity to modulation of noradrenergic systems might 
be anticipated to be associated with varying sympathetic nervous system 
activation, whereas activation of 5-HT2A/1A receptors would more likely 
predict hallucinogenic effects (Baumeister et al., 2015) (Table 1).  
Presenting with structural similarities to amphetamines (Feng et al., 2017), 
synthetic cathinones ([EMCDDA], 2017) are mostly inhibitors of the serotonin 
(SERT), dopamine (DAT) and noradrenaline (NET) transporters. These 
molecules can be further sub-categorised as: (1) cocaine/MDMA-like (3,4-
methylenedioxy-N-alkylated cathinones e.g. butylone): these act as inhibitors 
at SERT, DAT and NET and as serotonin releasers; (2) methamphetamine-like 
(N-alkylated or ring-substituted cathinones e.g. buphedrone): these act as 
inhibitors at SERT, DAT and NET and as dopamine releasers; and (3) 
pyrovalerone-like cathinones (N-pyrrolidine cathinones e.g. MDPV (3,4-
methylenedioxypyrovalerone): these are very potent at DAT and do not induce 
any monoamine substrate release (Simmler et al., 2013).  
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Apart from mephedrone (Dargan et al., 2010; De Sousa Fernandes Perna et 
al., 2016; Freeman et al., 2012; Karila et al., 2015; Karila et al., 2016; Prosser 
et al., 2012; Winstock, 2010; Winstock, 2011), the psychopathological 
consequences of most cathinones have not been fully studied. With 
mephedrone, low mood, loss of appetite, difficulty sleeping, levels of paranoid 
ideation, cognitive impairment, changes in perception, agitation, 
hallucinations, delusions, amnesia, confusion, violence and suicidal thoughts 
have been reported (Capriola, 2013; Herzig et al., 2013; Homman et al. 2018; 
John et al., 2017; Kaizer-Będkowska et al., 2018; Kehr et al., 2011; Lovrecic & 
Lovrecic, 2017). Users reported as well positive effects e.g. euphoria, improved 
psychomotor speed, alertness, and talkativeness (Cheng et al., 2012; Dargan 
et al, 2010; Mdege et al., 2017). Cathinone-induced acute intoxication may 
include symptoms of the serotonin syndrome, associated with aggression and 
hyperthermia, psychotic disorders, catatonia and excited delirium syndrome 
(Denysenko et al., 2015; Hohmann et al., 2014; Mugele et al., 2012; 
Otachbachi et al., 2010; Penders et al., 2012; Penders and Gestring, 2011; 
Warrick et al., 2013; Weaver et al., 2015). Other acute intoxication issues 
included dehydration, hypertension, tachycardia, kidney and liver impairment, 
electrolyte imbalance, metabolic toxicity, cerebral oedema, and death 
(Adebamiro & Perazella, 2013; Borek and Holstege, 2012; Imam et al., 2013). 
Suicides by hanging and deaths from firearm injuries have frequently been 
reported (Barrios et al., 2016; Marinetti and Antonides, 2013), as well as 
deaths from toxicity (Corkery et al., 2018b). Although long-term effects of 
synthetic cathinones’ use are largely unknown, they may include insomnia, 
depression, anxiety, psychosis, and dependence (Capriola, 2013). 
Phenethylamines are synthetic compounds available in tablets, capsules, and 
powder. They act on serotoninergic receptors, hence leading to psychedelic 
effects, but some of them inhibit the NA/DA reuptake as well. 3,4-
methylenedioxy-methamphetamine (MDMA, ‘ecstasy’) is one of the most 
popular drugs among youngsters/clubbers, because of its stimulant effects. 
Recently the emergence of a range of other psychedelic phenethylamines, 
including: the 2-C and 2-D series drugs; the benzodifurans (e.g. 3-C-bromo -
dragonfly), and others (e.g., 4-MTA, 6-APB, 4,4′-DMAR and PMA), has been 
reported (Miliano et al., 2016). Their psychoactive effects are dose-dependent, 
ranging from stimulant effects at lower doses, to hallucinogenic and 
entactogenic effects at higher doses. Phenethylamines’ intake may be 
associated with loss of appetite, tachycardia, hypertension, anxiety, nausea, 
headache, dizziness, skin irritation, hyperthermia, convulsions, respiratory 
deficits, liver/kidney failure and death (Schifano et al., 2015). Psychotic 
symptoms are associated with a high dosage intake (Baumeister et al., 2015) 
(Table 1).  
The lead compound in piperazines, N-Benzylpiperazine (BZP), has a typical 
central nervous system stimulant structure. Structurally similar to 
amphetamine and initially developed as an antidepressant, BZP triggers the 
release of DA and NA whilst inhibiting the uptake of DA, NA, and 5-HT (Miliano 
et al., 2016). Piperazines’ toxicity causes hallucinations, seizures, 
hyponatraemia, serotonin syndrome, renal failure and ultimately death 
(Schifano et al., 2015) (Table 1). 
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Tryptamines, with the most common molecule being the lysergic acid 
diethylamide/LSD, are a group of monoamine alkaloids very similar to the 
endogenous neurotransmitter serotonin. They act both as 5-HT2A receptor 
agonists and serotonin reuptake inhibitors. A large range of novel tryptamines, 
including: 5-MeO-AMT, 5-MeO-DALT, 4-HO-DALT, 5-MeO-DIPT; and 5-MeO-
DMT, have appeared on the drug scene (Miliano et al., 2016). Some of them 
are found in nature, e.g. Delosperma species plants (containing 
dimethyltryptamine/DMT; 5-MeO-DMT); hallucinogenic fungi (psilocin; 4-OH-
DMT); and amphibians (bufotenin) (Schifano et al., 2015). The predominant 
clinical effects of tryptamines consist in visual hallucinations, alterations in 
sensory perception, distortion of body image, depersonalization, marked mood 
lability and anxiety/panic. Untoward effects include agitation, tachyarrhythmia 
and hyperpyrexia. There are small numbers of tryptamine-related fatalities 
(Schifano et al., 2015) (Table 1).  
 
Prescription and OTC drugs 
Over the past decade the recreational use of several psychoactive 
pharmaceuticals has emerged in the NPS scene, including: antidepressants; 
antipsychotics; gabapentinoids; Z-drugs and designer benzodiazepines; and 
OTC drugs (Schifano et al., 2015; Schifano et al., 2018). 
 
1 Antidepressants 
Antidepressants emerged as being misused, raising public health concerns on 
their prescription control policies (Evans and Sullivan, 2014). Bupropion 
inhibits both the NA and DA reuptake (Schifano and Chiappini, 2018a) and, 
being a cathinone derivative, presents with stimulant activities (Baumeister et 
al., 2015; Evans and Sullivan, 2014).  It may be consumed orally, insufflated, 
or injected, with high dosages provoking a ‘high’ similar to cocaine (Vento et 
al., 2013). Adverse effects range from nasal pain to irritability, agitation, 
cardiac toxicity, hallucinations and seizures. Vulnerable users are inmates and 
patients with past histories of substance misuse (Schifano and Chiappini, 
2018a) (Table 1).  
Amitriptyline anecdotally emerged as the most abused among tricyclic 
antidepressants giving, at high dosages, ‘pleasant feelings’ and euphoria. Its 
anticholinergic and antihistamine effects may contribute to its abuse liability 
(Evans and Sullivan, 2014). Tachycardia and cardiac conduction changes are 
common in patients ingesting high dosages of tricyclic antidepressants; 
overdoses may be fatal (Shenouda and Desan, 2013) (Table 1).  
At high/supratherapeutic doses (e.g. 400-4,000mg/day), the phenylethylamine 
derivative venlafaxine (‘baby ecstasy’) inhibits the reuptake of serotonin, 
noradrenalin, and dopamine, particularly at the prefrontal cortex level 
(Francesconi et al., 2015). If suddenly discontinued, a withdrawal syndrome 
characterized by nausea, depression, suicidal thoughts, disorientation, stomach 
cramps, panic attacks, sexual dysfunction, headache, and occasional psychotic 
symptoms may develop (Table 1).  
 
2 Antipsychotics 
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Quetiapine ([FDA], 2010) recently emerged on the drug scenario as being used 
for recreational purposes (Klein et al., 2017), which may have contributed to 
increased poisonings and related fatalities (Lee et al., 2018). Crushed 
quetiapine tablets can be self-administered through nasal insufflation, 
ingested, or injected (Chiappini and Schifano, 2018). The intentional abuse of 
quetiapine is associated with sedation and euphoria (Lee et al., 2018). 
Quetiapine is also abused concomitantly with other illicit substances, such as 
cocaine (‘Q ball’; Lee et al., 2018). At high/supratherapeutic dosages, a 
quetiapine agonist activity on the DA system has been hypothesized (Chiappini 
and Schifano, 2018). Vulnerable subjects include inmates and those with a 
previous substance abuse history (Lee et al., 2018) (Table 1).  
Olanzapine, at a dosage of up to 50 mg/day, has been anecdotally advised 
online as the ‘ideal trip terminator’ after a psychedelic drug binge. Moreover, it 
may be used to treat unwanted ‘comedown’ symptoms (depression, dysphoria, 
anxiety, and insomnia) from drug/alcohol intake (Chiappini and Schifano, 
2018; Klein et al., 2017) (Table 1). 
 
3 Gabapentinoids 
A rise in pregabalin and gabapentin prescription rates has been registered 
worldwide, with an anecdotally growing black market (Parsons, 2018). Both 
gabapentinoids bind to the calcium channel, reducing the release of excitatory 
molecules. At therapeutic dosages, they are thought to possess GABA‐mimetic 
properties, which may be behind the ‘liking’ (euphoric/relaxing high), but 
causing only limited rewarding (‘wanting’), dopaminergic-related, properties 
(Berridge and Robinson, 2016; Bonnet and Scherbaum, 2017; Bonnet et al., 
2018). A range of experiences may be associated with gabapentinoid high-
dosage abuse, including euphoria, improved sociability, opiate-like sedation, 
entactogenic feelings/dissociation, and psychedelic effects (Schifano et al., 
2015). Gabapentinoids may be ingested to cope with opiate/opioid withdrawal 
symptoms (Schifano et al., 2018). Unconventional routes of administration 
have been reported, e.g. intravenous; rectal – ‘plugging”’; smoking; and 
‘parachuting’, e.g. emptying the content of the capsule into a pouch (Al-
Husseini et al., 2018; Chiappini and Schifano, 2016). A proper withdrawal 
syndrome, including: insomnia; headache; nausea; anxiety; and convulsions, 
can be associated with gabapentinoids’ abrupt discontinuation (Baumeister et 
al., 2015; [WHO], 2017) (Table 1). 
 
4 Z-drugs and designer benzodiazepines 
The Z-drugs’ (zolpidem, zopiclone and zaleplon) addictive potential has already 
been highlighted (Kapil et al., 2014; Schifano et al, 2019). Zolpidem and 
zopiclone seem to be the most involved in the diversion and abuse phenomena 
([ACMD], 2013), and it is likely that the misusing phenomenon is currently 
underestimated (Hajak et al., 2003). A 20 mg to 300–400 mg/day zolpidem 
dosage has been associated with significant stimulating effects, hyperactivity 
and euphoria (Victorri-Vigneau et al., 2007) (Table 1). Polydrug consumption 
and history of drug misuse are frequently reported issues; both snorting and 
injection practices have been described. A withdrawal syndrome may develop 
after the abrupt cessation of Z-drugs’ long-term, high-dosage, intake and 
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symptoms may include insomnia, anxiety, irritability, tremor, abdominal pain, 
hypertension, tonic-clonic seizures, and confusion.  
Designer benzodiazepines recently emerged on the illegal drug scene 
([EMCDDA], 2017; Graddy et al., 2018; Vårdal et al., 2019). Most of them are 
not approved for therapeutic use in any country (Baumeister et al., 2015; 
Moosmann et al., 2015) and may be easily acquired online (Vårdal et al., 
2019). Whilst sharing clinical effects with ‘traditional’ molecules (Baumeister et 
al., 2015), some designer benzodiazepines (e.g. pyrazolam; 
phenazepam/’Zinnie’) may be several times more potent than diazepam 
(Moosmann et al., 2015; Schifano et al., 2015; Tracy et al., 2017). Designer 
benzodiazepines’ side-effects include amnesia, long-lasting (60 hours) 
confusion and disorientation, dizziness, loss of coordination, drowsiness, 
blurred vision, slurred speech and ataxia (Baumeister et al., 2015). Due to 
their high potency, molecules such as clonazolam or flubromazolam can cause 
strong sedation and amnesia at oral doses as low as 0.5 mg, hence they may 
be unintentionally overdosed (Moosmann et al., 2015). Etizolam, phenazepam, 
clonazolam, diclazepam, phenazolam, and flubromazolam have all been 
involved in fatalities ([UNODC], 2018) (Table 1).  
 
5 OTC drugs 
Over the last decade, clinicians have raised concerns relating to a range of 
OTCs being misused recreationally, with ‘pharming’ (e.g. shopping from a 
range of pharmacy shops) being an internationally recognized issue (Schifano 
and Chiappini, 2018b). OTC misuse may have developed due to their increased 
availability, affordability, and users’ perceptions on their safety (Cooper, 2013; 
Sansgiry et al., 2016). Commonly abused medications include ephedrine and 
pseudoephedrine; codeine-containing antitussives; and dextromethorphan 
(Cooper, 2013). Codeine diversion has been reported to be associated with 
sedating effects, whilst its combination with promethazine is known as ‘purple 
drank’ (Cooper, 2013) (Table 1).  
Dextromethorphan (DXM) is a cough suppressant opioid derivative, considered 
safe at recommended dosages, e.g. 120 mg in four divided doses per day (Linn 
et al., 2014). The psychotropic effects and addictive potential are associated 
with the intake of large dosages, typically administered through snorting or 
injecting practices. Psychotropic effects include trance-like euphoria/stupor, 
hyper excitability, depersonalization, dyskinesia, delayed response times, 
disordered speech, and vivid auditory/visual hallucinations (Romanelli and 
Smith, 2003). Due to the action of DXM’s primary metabolite dextrorphan on 
the NMDA receptor, the compound may produce a ketamine-like dissociative 
state, known as ‘robo-ing’, ‘robo-copping’, or ‘robo-tripping’, after the DXM-
containing cough syrup commercial name (Wilson et al., 2011). Moreover, DXM 
chronic abuse has been associated with psychosis (Linn et al., 2014). In 
addition to NMDA receptor antagonist activity, DXM and its metabolite 
dextrorphan are specific serotonin reuptake inhibitors. As a result, the acute 
DXM intoxication has been linked to a serotonin syndrome, especially if used 
together with remaining serotonergic agents (Linn et al., 2014) (Table 1). 
Recently, the anti-diarrhoeal opiatergic compound loperamide has been 
reported for its euphoric effects (Lee et al., 2019; ). At therapeutic dosages (2-
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16mg/day), due to both rapid metabolism and poor blood–brain barrier 
penetration, it is considered safe. However, when self-administered at high 
dosages (e.g. >50mg), its µ-opioid receptors’ agonist activities explain why 
‘lope’, being anecdotally described as ‘better than oxycodone’, has been 
associated with euphoria, central nervous system depression, and fatal 
cardiotoxicity. Cytochrome inhibitors, such as cimetidine, omeprazole and 
grapefruit juice, as well as P-glycoprotein inhibitors, such as quinidine-quinine 
and pepper, may be concomitantly used to raise the drug blood levels (Baker, 
2007; Schifano and Chiappini, 2018b) (Table 1).  
 
Discussion   
 
The present paper has provided an updated review of both the large number of 
NPS and their associated psychopathological consequences. In recent years, 
the large access to the web has led to a gradual, although partial, shift from a 
‘street’ to a ‘web’ market (Corkery et al., 2017). Both the ‘open’ but also the 
‘deep web’ and the ‘dark net’ (Orsolini et al., 2015), with their fora, blogs, 
social networks and chat rooms, are in a continuous development. These 
represent large-scale, international, shared platforms that facilitate the 
occurrence of confidential exchange of drug-related information, but which also 
directly/indirectly promote the acquisition of a range of new, emerging, and 
untested psychoactive substances (Schifano and Orsolini, 2015). This has 
facilitated the growth of a completely uncontrolled and ‘quasi-legal’ market for 
many psychoactive substances. The use of NPS is mostly self-experimental in 
nature, ad one could argue that the ‘e-psychonauts’ (Orsolini et al., 2015) are 
those who properly shape and influence current and possibly future drug 
scenarios. Indeed, the e-psychonauts seem to test, and at times synthesize, a 
range of drugs to achieve the state of consciousness they find most 
pleasurable (Orsolini et al., 2015). It is intriguing that, whilst navigating the 
online psychonauts’ fora with NPS.Finder®, a few thousands NPS were here 
identified, a number which is about 4-fold higher than what identified by both 
the EMCDDA ([EMCDDA], 2018a) and the UNODC ([UNODC], 2018). Hence, it 
is here suggested that carrying out systematic web crawling activities may help 
in designing and developing a range of NPS-related early recognition and 
monitoring programmes. Further studies from our group will hopefully better 
identify: (a) which of the e-psychonauts’ molecules will enter the future 
markets; and (b) which is the time gap, for an index NPS, between the start of 
the e-psychonauts’ interest and the actual identification on the international 
drug scenarios.   
The ever-increasing changes in terms of recreational psychoactives’ availability 
represent a relatively new challenge for psychiatry. These molecules’ intake 
may be risky, and the pharmacodynamics and pharmacokinetics of many NPS 
are still poorly understood (Schifano et al., 2016). Overall, the intake of these 
substances is typically associated with an imbalance of a range of 
neurotransmitter pathways/receptors, and consequently with the risk of 
psychopathological disturbances. The occurrence of psychopathological 
disturbances has been related here to the significant imbalance of a range of 
neurotransmitters/pathways: (a) increased central dopamine levels, mostly 
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associated with psychedelic phenethylamines and synthetic cathinones; (b) 
agonist/super agonist cannabinoid CB1 receptor activation, achieved with 
synthetic cannabimimetics; (c) 5-HT2A receptor activation, reported with latest 
tryptamine derivatives, DXM and hallucinogenic plants; (d) antagonist activity 
at NMDA receptors, described with phencyclidine-like dissociatives; and (e) k-
opioid receptor activation, typically associated with Salvia divinorum intake. As 
NPS are presumably more often used in hedonistic and sporadic occasions, the 
acute physical and psychiatric complications are perhaps of special importance 
compared to the risk of addiction development observed with the traditional 
illicit psychoactive substances, which are more often used on a daily basis over 
an extended period of time.  
It is difficult for mental health professionals to keep up-to-date with the 
growing number of NPS being made available. Clinicians are not always aware 
of the psychopathological risks relating to NPS intake, and, at the same time, 
they are not typically able to identify a potential NPS user (Simonato et al., 
2013). This may be a reason for concern, especially for emergency mental 
health clinicians confronting with acute, and at times dramatic, clinical 
situations which are suspected of being drug-related but in which the standard 
urine specimen turns out to be negative. In fact, standard toxicity tests are 
able to identify just a few misused molecules and only expensive, lengthy, 
tests carried out in specialized settings are able to identify the vast range of 
NPS available (Smith et al., 2015). Hence, clinicians should be informed about 
the range of NPS; their intake modalities; their psychoactive sought-after 
effects; the idiosyncratic psychotropics’ combinations; and finally, their 
psychopathological risks (Orsolini et al., 2015). Thus, further research studies 
should focus on drafting specific guidelines to better help clinicians in treating 
and managing the acute and long-term psychopathological consequences of 
NPS intake. 
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Table 1: Main categories of Novel/New Psychoactive Substances (NPS) 
and their effects  
 
SUBSTANCES DESIRED EFFECTS                          ADVERSE EFFECTS 
 
  Psychopathological 
symptoms 
Physical symptoms 
Synthetic cannabimimetics 
(SC) 
 
 
Intense cannabis-like effects 
such as euphoric feelings and 
relaxation, associated with 
auditory/visual hallucinations   
Acute: auditory/visual 
hallucinations, anxiety, 
intense feelings of 
paranoia, behavioural 
dyscontrol and agitation, 
mood swings, suicidal 
ideation, suicide attempts, 
panic attacks, thought 
disorganization, 
agitated/excited delirium, 
florid/acute transient 
psychosis, relapse/ 
worsening of a pre-existing 
psychosis, relapse of a 
pre-existing bipolar 
disorder.   
 
Chronic: persistent 
psychotic disorder, HPPD, 
‘Spiceophrenia’.  
SC use can give rise to 
dependence, tolerance 
and withdrawal (drug 
craving, feelings of 
emptiness/depression, 
anxiety, irritability, mood 
swings, and 
insomnia/nightmares). 
 
Acute: Typical acute medical 
untoward effects include 
vomiting/nausea; hypertension 
and tachycardia; tachypnoea/ 
dyspnoea; hyperglycaemia; 
mydriasis, nystagmus; 
seizures, encephalopathy, 
coma; and stroke. Fatalities 
may occur. 
   
Chronic: Withdrawal symptoms 
may include diaphoresis, 
headache, tachycardia, tremor, 
diarrhoea, headache, 
insomnia. 
 
New synthetic opioids (NSOs) 
(e.g., U-47700, U-49900, AH-
7921, U-50488, U-51754, MT-
45, acetylfentanyl, carfentanyl, 
furanylfentanyl) 
 
 
 
 
 
 
 
 
 
 
 
Desomorphine (‘krokodil’) 
 
 
 
 
 
 
 
 
 
 
 
 
Mitragynine (‘Kratom’, ‘kakuam’, 
‘thang’, ‘ketum’, ‘biak’)  
 
 
 
 
 
 
 
 
Euphoria, sedation, feeling of 
relaxation, dissociating effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Morphine analogue with high 
potency due to high lipophilicity, 
fast onset of action, and short 
duration of effects. Euphoria, 
pleasure, relaxation. 
 
 
 
 
 
 
 
 
In low doses, mild stimulant 
effects (euphoria, increased 
energy, relaxation) 
 
 
 
 
 
 
 
Acute: mood lift, dysphoric, 
dissociation, intense 
sedation, disorientation, 
confusion.  
 
 
 
 
Chronic: tolerance, 
addiction, withdrawal 
(similarly to the traditional 
opioid withdrawal, 
restlessness, agitation, 
insomnia). 
 
 
Acute: mood lift, dysphoric 
mood and dissociation, 
sedation, disorientation, 
confusion.  
 
 
Chronic: tolerance, 
addiction, withdrawal 
(similarly to the traditional 
opioid withdrawal, 
restlessness, agitation, 
insomnia) 
 
At high dosages: sedative-
narcotic effects, confusion. 
 
 
 
 
 
 
 
 
Acute: Constipation, nausea, 
drowsiness, miosis, slurred 
speech, poor coordination, 
slowed breathing rate and 
respiratory depression, coma, 
death. 
Chronic: tolerance, addiction, 
withdrawal symptoms. Opioid 
toxicity effects, including death 
from overdose. Furthermore: 
damage of skin, blood vessels, 
bone and muscles surrounding 
the entry-point of the injection. 
 
 
 
Acute: Constipation, nausea; 
risk of slowed breathing rate 
and respiratory depression, 
coma, death. 
 
 
Chronic: tolerance, addiction, 
withdrawal symptoms. Opioid 
toxicity effects, including death 
from overdose. 
 
 
 
Acute: severe nausea, 
vomiting, stomachache, and 
constipation associated with 
visual disturbances; death 
possible in combination with 
other substances and/or in 
association with underlying 
health conditions. Occasionally 
causes death on its own.  
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Salvinorin A (Salvia divinorum, 
hierba de Maria’, ‘Maria pastora’, 
‘Sally-D’, ‘magic mint’) 
 
 
 
 
 
 
 
Potent hallucinogenic effects, 
with time distortion, vivid 
imagery; empathogenic effects. 
 
 
 
 
 
 
 
Perceptual disturbances; 
psychosis; irritability; and 
anxiety, HPPD. 
Chronic: intrahepatic 
cholestasis and other liver 
disease, along with 
hypothyroidism; dependence 
and opioid‐like withdrawal 
symptoms. 
 
Deaths may occur as a result of 
the subject idiosyncratic 
behaviour. 
Ketamine-like dissociatives    
 
Ketamine (‘ket’, ‘special K’, 
‘super K’, ‘kit-kat’) 
 
Dissociation, depersonalization, 
intense detachment and near-
death experiences (‘K-hole’), 
perceptual disorders, auditory 
and visual hallucinations. 
 
Acute: anxiety, 
dissociation, 
depersonalization, 
perceptual distortions, 
auditory and visual 
hallucinations, flashbacks, 
‘K-hole’. 
 
Chronic: impairment of 
attention and recall, 
psychosis, perceptual 
disorders, HPPD, 
dependence can occur. 
 
Acute: tachycardia, agitation, 
hypertension, nausea, slurred 
speech, dizziness, collapse. 
Accidental injury, risk of 
trauma, drowning, death from 
hypothermia and traffic 
accidents. 
 
Chronic: subtle visual anomaly, 
impairment of motor function, 
urological dysfunctions (‘K-
bladder’), rhabdomyolysis, 
intestinal symptoms (‘K-
cramps’). 
 
 
Phencyclidine (PCP, ‘angel 
dust’, ‘supergrass’, ‘boat’) and 
PCP-type substances (e.g., 3-
MeO-PCE, 4-MeO-PCP) 
 
Distorted perceptions of sight 
and sound, dissociation from the 
environment, out-of-body 
experiences, hallucinations. 
 
Acute: cognitive changes, 
such as memory 
impairments, altered 
perception of time, 
slowness, anxiety, apathy, 
irritability, psychosis, 
stupor, coma, violent 
behaviour. 
 
 
Chronic: cognitive 
impairment, mood shifts, 
anxiety disorders, suicidal 
thoughts, dependence. 
 
 
Acute: increase in breathing 
rate, elevated blood pressure, 
tachycardia, flushing and 
excessive sweating, nausea, 
vomiting, blurred vision, loss of 
balance, dizziness, kidney 
failure, seizures, cardiac arrest 
and cerebrovascular 
accidents. 
 
Chronic: dependence and 
withdrawal symptoms. 
 
Methoxetamine (‘mexxy’, ‘special 
M’) 
 
 
Relaxation, euphoria. 
Dissociative and 
sympathomimetic effects. More 
intense and longer lasting effects 
than ketamine (‘M-hole’: state of 
profound and long-lasting 
dissociation).  
 
Acute: dissociation, 
hallucinations 
 
 
 
 
 
 
 
Chronic: neurocognitive 
deficits and deterioration in 
mood, perceptual 
distortions. 
 
Acute: tachycardia, 
hypertension, cerebellar 
toxicity (loss of balance, 
slurred speech), seizures, 
nausea, vomiting, and 
diarrhoea, cardiac arrhythmias 
and blackouts; accidental 
deaths. 
  
Chronic: gastrointestinal 
symptoms (M-cramps), severe 
ulcerative cystitis and renal 
damage. 
 
Novel Stimulants and novel 
psychedelics  
 
Synthetic cathinones (e.g., 
mephedrone, ‘m-cat’; ‘meow’) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stimulant (increased alertness, 
feeling ‘high’) effects, similar to 
amphetamine; euphoria, feeling 
of wellbeing and energy, feeling 
of self-confidence. 
 
 
 
 
 
 
 
 
 
 
Acute: agitation, 
restlessness, anxiety, 
paranoid ideation, 
aggression and violence, 
insomnia. 
 
 
 
 
Chronic: insomnia, 
depression, anxiety, 
paranoid ideation, 
 
 
 
Acute: tachycardia, 
hypertension, hyperthermia, 
anorexia, dizziness, headache, 
angina pectoris, myocarditis, 
abdominal pain, 
rhabdomyolysis, convulsions 
and death. 
 
Chronic: hypertension, 
tachycardia, kidney damage 
and failure, liver damage, 
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Psychedelic/empathogenic 
phenethylamines (e.g., 2C 
series; D series, such as DOI, 
DOC; benzodifurans, such as 
‘bromodragonfly’; others, such 
as PMA/PMMA) 
 
 
 
 
 
 
 
 
 
 
 
Piperazines (e.g., BZP, mCPP, 
‘party pills’, ‘smileys’) 
 
 
 
 
 
 
Tryptamines (e.g., DMT, 5-MeO-
DMT, ‘magic mushrooms’)   
 
 
 
 
 
Dose-dependent effects, ranging 
from mere stimulant effects 
(energy, euphoria, increased 
locomotor activity, talkativeness, 
disinhibition, alertness, sexual 
arousal) at low doses and 
psychedelic (hallucinations and 
dissociation) and/or 
empathogenic effects at higher 
dosages. 
 
 
 
 
 
 
 
Euphoric effects similar to 
amphetamines; hallucinogenic 
effects at higher doses. 
 
 
 
 
 
Mild stimulation, euphoria, 
intensified sensual or sexual 
feelings, visual hallucinations, 
alteration in sensory perception, 
depersonalization. 
psychosis, dependence 
and addiction.  
 
Acute: dysphoria, 
hallucinations.  
 
Chronic: cognitive 
impairment, depression, 
increased suicide risk. 
 
 
 
 
 
 
 
 
 
 
 
Dissociation, perceptual 
distortion. 
 
 
 
 
 
 
Acute: dysphoria, panic, 
paranoid feelings. 
 
Chronic: flashbacks, 
HPPD, dependence (rare). 
muscle tissue damage, brain 
tissue damage 
 
 
 
Acute: hypertension, vomiting, 
hyperthermia, convulsions, 
hyponatraemia, anorexia, 
mydriasis, tachycardia, 
serotonin syndrome, collapse, 
dizziness, hallucinations, 
headache, sweating, delayed 
orgasm, erectile dysfunction, 
respiratory deficits, liver and 
kidney failure, and death  
 
Chronic: cognitive impairment, 
neurotoxicity.  
 
 
 
 
Hyperthermia, 
rhabdomyolysis, convulsions, 
serotonin syndrome and 
kidney failure; death has been 
reported at high doses. 
 
 
 
Acute: agitation, tremor, 
tachycardia, hyperthermia, 
restlessness, gastrointestinal 
distress, muscle tension, 
rhabdomyolysis. Fatalities 
possible. 
 
Prescription drugs with a 
misusing potential  
   
1. ANTIDEPRESSANTS: 
 
Bupropion 
 
 
 
 
 
Amitriptyline 
 
 
 
 
 
 
 
 
Venlafaxine (‘baby ecstasy’) 
 
 
 
‘High’ similar to cocaine abuse at 
high dosages, but of lesser 
intensity. 
 
 
 
Pleasant feelings, sociability and 
euphoria at high dosages. 
 
 
 
 
 
 
 
MDMA/amphetamine‐like 
stimulant and psychedelic effects 
at high dosages. 
 
 
 
Agitation, dysphoria, 
irritability, hallucinations 
 
 
 
 
High dosages: Agitation, 
dysphoria 
 
 
 
 
 
 
 
Acute: Agitation, 
dysphoria, irritability 
 
Chronic: withdrawal 
symptoms, such as, 
depression, irritability, 
insomnia, suicidal 
thoughts, disorientation, 
panic attacks, and 
psychotic symptoms. 
 
 
 
Tremor, agitation, vomiting, 
tachycardia, cardiac toxicity, 
hallucinations, seizures, death. 
 
 
 
Tachycardia and cardiac 
conduction changes; nausea, 
vomiting, dry mouth, difficulty 
urinating, blurred vision, 
confusion, dizziness, 
dissociation, seizures, coma, 
death. 
 
 
Acute: autonomic 
hyperactivity, tachycardia, 
hypertension, chest pain 
 
Chronic: if abruptly stopped, 
withdrawal symptoms, such as: 
nausea, tremors, insomnia, 
stomach cramps, sexual 
dysfunction, and headache can 
occur 
 
2. ANTIPSYCHOTICS: 
 
Quetiapine (‘Susie Q’, ‘Quell’, 
and ‘baby heroin’); ‘Q ball’ 
(quetiapine with cocaine); ‘MaQ 
ball’ (quetiapine and marijuana). 
 
 
 
 
 
Intense sedation; euphoria.  
 
 
 
 
 
 
 
 
Acute: sedation, 
perceptual distortion  
 
Chronic: withdrawal 
symptoms may occur if 
high-dosage/long-term 
intake abruptly stopped; 
 
 
Acute: drowsiness, lethargy, 
hypotension, tachycardia, 
coma, respiratory depression, 
seizure, and death. 
 
Chronic: weight gain, 
increased risk of heart disease; 
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Olanzapine (‘Lilly’) 
 
 
 
 
 
 
 
 
Relaxing and sedating effects; 
being anecdotally considered the 
‘ideal trip terminator’ after a 
psychedelic drug binge or as a 
self-treatment of unwanted 
‘comedown’ symptoms 
(depression, dysphoria, anxiety, 
and insomnia) from drug/alcohol 
intake. 
 
agitation, anxiety, difficulty 
with concentration, 
insomnia, mood swings, 
psychotic symptoms, and 
suicidal thoughts or 
behavior can occur as a 
result. 
 
Acute: relaxation, sedation 
 
Chronic: discontinuation 
symptoms after long-term 
usage: anxiety, dysphoria, 
insomnia. 
withdrawal syndrome physical 
signs/symptoms may include 
nausea and vomiting, agitation, 
dizziness, irregular heartbeat, 
headache. 
 
 
 
Acute: drowsiness, slurred 
speech, confusion.  
 
Chronic: discontinuation 
symptoms after long-term 
usage, including irritability, 
dysphoria, insomnia, and 
nervousness. 
 
3. GABAPENTINOIDS 
(pregabalin and gabapentin) 
 
 
Abuse of high doses may cause: 
euphoria, improved sociability, 
opiate‐like sedation, 
entactogenic 
feelings/dissociation, and 
psychedelic effects. Pregabalin 
action is more potent, with faster 
onset and greater bioavailability 
compared with gabapentin, 
hence characterized by 
potentially higher misusing 
potential.  
 
 
Acute: anxiety; irritability, 
sedation, seizures. 
 
 
 
 
Chronic: dependence and 
withdrawal symptoms, 
suicidal behaviour. 
 
Acute: clinical scenario similar 
to alcohol intoxication, with 
profound sedation and coma. 
Deaths may occur. 
 
Chronic: Gabapentinoid 
withdrawal syndrome may 
include insomnia; headache; 
nausea; and convulsions.  
 
4. Z-DRUGS (zaleplon, zolpidem 
and zopiclone) 
 
 
High dosages are associated 
with intense stimulating effects, 
hyperactivity and euphoria 
(>>>zopiclone).  
 
Sedation 
 
Withdrawal symptoms may 
include: insomnia, anxiety, 
irritability, tremor, restlessness, 
speech difficulties, abdominal 
pain, hypertension, tonic-clonic 
seizures, 
confusion/disorientation. 
 
 
DESIGNER 
BENZODIAZEPINES (e.g., 
clonazolam, etizolam, 
flubromazepam, phenazepam 
(‘Zinnie’) and pyrazolam  
 
Sedative, anxiolytic, hypnotic 
properties. May be ingested as 
‘self-medication’ by users of 
stimulant and hallucinogenic 
drugs.  
 
Sedation 
 
Acute: drowsiness, confusion, 
unsteady walking, slurred 
speech, blurred vision, poor 
concentration, dizziness, 
amnesia, disorientation, 
sedation, slowed breathing, 
death. 
 
Chronic: impaired cognition, 
physiological and mental 
health sequelae consistent 
with traditional 
benzodiazepines; addiction 
and withdrawal symptoms, 
including seizures. 
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5. OVER-THE-COUNTER 
DRUGS: 
 
Codeine (‘Purple drank’ is a mix 
of codeine and promethazine) 
 
 
 
 
 
 
 
 
 
 
 
Loperamide 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dextromethorphan (DXM)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Calming and euphoric effects. 
 
 
 
 
 
 
 
 
 
 
 
 
Euphoria (‘Lope highs’), can 
occur after consuming large/very 
large dosages; may be used to 
alleviate opiate/opioid withdrawal 
(the ‘poor man methadone’).  
  
 
 
 
 
 
 
 
 
 
 
Dose-related effects, with trance-
like euphoria or stupor, 
hyperexcitability, and vivid 
auditory/visual hallucinations; 
ketamine-like dissociative state 
(‘robo-ing’, ‘robo-copping’, or 
‘robo-tripping’) possible. 
 
  
 
 
 
 
 
 
 
Acute: Mood swings, 
irritability, anxiety, apathy, 
memory loss, delusions 
and hallucinations.  
 
 
Chronic: tolerance, 
withdrawal and 
dependence, typically 
developing as with other 
opioids 
 
 
Acute: sedation 
 
 
Chronic: addiction. As with 
traditional abused opioids, 
withdrawal symptoms, 
include anxiety, 
restlessness, depression, 
agitation. 
 
 
 
 
 
 
 
Acute: dizziness, altered 
mental status, delayed 
response times, 
disordered speech, 
depersonalization, and 
dissociation.  
 
 
Chronic: psychosis, 
HPPD, tolerance and 
dependence. Withdrawal 
symptoms may include 
intense cravings, anxiety, 
panic attacks, irritability, 
insomnia and nightmares, 
memory issues, 
flashbacks. 
 
 
 
Acute: Sedation, drowsiness, 
dizziness, nausea and 
vomiting, decreased libido, 
constipation, seizures, and 
respiratory depression. 
 
Chronic: tolerance, withdrawal 
and dependence, typically 
developing as with other 
opioids 
 
 
 
Acute: unconsciousness, 
constipation, kidneys or liver 
dysfunction, respiratory 
depression, urinary retention, 
CNS depression and fatal 
cardiotoxicity, with high/very 
high QTc levels. 
 
Chronic: addiction. Similarly to 
other opioids, withdrawal 
symptoms include nausea, 
muscle cramps, excessive 
sweating, opioid cravings. 
 
 
 
Acute: nausea, vomiting, 
dyskinesia, seizures, liver 
failure, hyperthermia, 
respiratory depression, coma. 
The acute intoxication has 
been linked to the serotonin 
syndrome, especially if used 
together with molecules acting 
on the serotoninergic 
neurotransmission. 
  
Chronic: withdrawal syndrome 
may develop after a long-term 
use of high doses of DXM, and 
may consist of craving, fatigue, 
diaphoresis, nausea, 
hypertension, and tachycardia, 
gastrointestinal distress 
(vomiting, diarrhoea), 
insomnia. 
 
DXM: Dextromethorphan, SC: Synthetic Cannabinoids, HPPD: Hallucinogen-Persisting Perception Disorder 
 
 
